文献速递其他结缔组织病

靶向蛋白质组学识别原发性干燥综合征合并淋巴瘤的差异表达蛋白

Targeted proteomics identifies differentially expressed proteins in Sjögren's disease with incident lymphoma.
PubMed 文献 · RMD Open · 2025-10-23

该研究采用Olink Target 96 Immuno-Oncology panel分析血清蛋白,比较18例干燥综合征(SjD)合并新发淋巴瘤患者与无淋巴瘤SjD、健康对照的差异。发现18个差异表达蛋白,其中TNFSF14、FGF2、IL8、CD40和CXCL13上调最显著,CXCL13是随访中唯一下降的蛋白;所有SjD组干扰素激活评分升高,淋巴瘤前组最明显。

要点

  • SjD合并新发淋巴瘤患者血清中TNFSF14、FGF2、IL8、CD40和CXCL13等18个蛋白差异表达。
  • CXCL13是随访中唯一水平下降的差异蛋白。
  • 淋巴瘤前SjD组CD40表达上调,且干扰素激活评分最显著升高。

核心结论

  • SjD合并新发淋巴瘤及淋巴瘤前状态存在血清蛋白表达改变和干扰素系统激活增强。

研究设计与样本

  • 纳入SjD合并新发淋巴瘤患者18例(治疗前及随访6、12、24个月采血),淋巴瘤诊断前1-5年采血者4例,对照包括无淋巴瘤SjD 21例、历史淋巴瘤SjD 6例和健康献血者39例。
  • 采用Olink Target 96 Immuno-Oncology panel检测血清蛋白,差异表达分析采用FDR校正P值0.05,并计算蛋白衍生的干扰素激活评分(pIFN评分)。

主要发现

  • 与无淋巴瘤SjD和健康对照相比,SjD合并新发淋巴瘤患者共鉴定出18个差异表达蛋白。
  • 上调最显著的蛋白包括TNFSF14、FGF2、IL8、CD40和CXCL13,其中CXCL13是随访中唯一水平下降的蛋白。
  • 淋巴瘤前SjD组CD40表达较无淋巴瘤SjD组和健康对照组上调。
  • 所有SjD患者组的pIFN评分均高于健康对照,其中淋巴瘤前SjD组干扰素激活最显著。

关键数值与推荐

  • 差异表达蛋白判定采用FDR校正P值<0.05。
  • SjD合并新发淋巴瘤组鉴定出18个差异表达蛋白(对比无淋巴瘤SjD和健康对照)。
  • 上调最显著的蛋白为TNFSF14、FGF2、IL8、CD40和CXCL13;CXCL13在随访中水平下降。
  • 淋巴瘤前SjD组CD40表达上调;所有SjD组pIFN评分高于健康对照,淋巴瘤前组最显著。

临床怎么用

  • 上述血清蛋白标志物及pIFN评分可能有助于早期识别SjD高淋巴瘤风险患者,并可能为治疗靶点提供线索。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Patients with primary Sjögren's disease (SjD) have an increased risk of B cell lymphoma. The aim of this study was to determine serum protein biomarkers for lymphoma development and to advance our understanding of the functional mechanisms underlying lymphomagenesis in SjD. METHODS: Patients with SjD and incident, current lymphoma (n=18) with serum sampled before treatment and at 6, 12 and 24 months of follow-up, and four patients sampled 1-5 years before lymphoma diagnosis (pre-lymphoma) were included. SjD without lymphoma (n=21), SjD with historical lymphoma (n=6) and healthy blood donors (n=39) served as controls. Differentially expressed proteins between groups were analysed using the Olink Target 96 Immuno-Oncology panel applying a false discovery rate (FDR) adjusted p value of 0.05. Protein-derived interferon activation scores (pIFN scores) were calculated. RESULTS: We determined 18 differentially expressed proteins in SjD with incident lymphoma compared with both SjD without lymphoma and healthy controls. Among the top upregulated proteins were TNFSF14, FGF2, IL8, CD40 and CXCL13, where CXCL13 was the only protein with decreased levels at follow-up. We also observed upregulated expression of CD40 in the SjD pre-lymphoma group compared with SjD without lymphoma and healthy controls. All SjD patient groups presented elevated pIFN scores compared with healthy controls, where SjD sampled pre-lymphoma showed the most distinct IFN activation. CONCLUSIONS: We identified altered protein expression and an increased IFN system activation in SjD with incident lymphoma and pre-lymphoma. This knowledge may contribute to earlier detection of high-risk patients, identification of therapeutic targets and may ultimately improve SjD patient outcomes.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Imgenberg-Kreuz J, Fugmann C, Molin AM, et al. Targeted proteomics identifies differentially expressed proteins in Sjögren's disease with incident lymphoma. RMD Open. 2025. PMID: 41130745. doi:10.1136/rmdopen-2025-005897

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。